Abelacimab Shows Consistent Bleeding Safety Across Kidney Function in Atrial Fibrillation: Insights from the AZALEA-TIMI 71 Trial

Highlight

• Abelacimab significantly reduces major and clinically relevant nonmajor (CRNM) bleeding compared to rivaroxaban across a broad spectrum of kidney function in atrial fibrillation (AF) patients.
• Patients with impaired kidney function (creatinine clearance ≤50 mL/min) on rivaroxaban had higher bleeding rates despite dose adjustment, while abelacimab’s safety was consistent regardless of renal function.
• Absolute bleeding risk reduction with abelacimab was most pronounced in patients with moderate renal impairment.
• These findings suggest abelacimab offers a potentially safer anticoagulation option for AF patients with chronic kidney disease (CKD), pending further studies on stroke prevention efficacy.

Study Background and Disease Burden